Forbes February 13, 2025
Demaris Mills is president at Integrated DNA Technologies, a global genomics solutions provider.
In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first FDA-approved CRISPR-Cas9 gene editing treatment. The therapy—which involves removing blood stem cells from patients, editing them and then reinfusing them—can take up to a year for patients to complete. It’s groundbreaking nonetheless because the one-time CRISPR process reduces the activity of a gene that contributes to the painful blood disorder, and in so doing, it offers patients the chance of a normal life.
As we begin a new year, it’s a good time to look forward to the...
Today's Sponsors
Today's Sponsor